M1 Kliniken AG Stock
M1 Kliniken AG Stock
M1 Kliniken AG took a tumble today and lost -€1.160 (-6.010%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for M1 Kliniken AG stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of M1 Kliniken AG in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of M1 Kliniken AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| M1 Kliniken AG | -6.010% | 0.781% | 26.294% | 7.500% | 8.468% | 200.000% | 95.879% |
| Mediclin AG | -0.530% | 9.302% | 4.444% | 49.206% | 57.983% | 9.942% | 0.000% |
| Vita 34 AG | -3.700% | 3.846% | -3.571% | 35.000% | 31.068% | -33.333% | -56.275% |
| Surgery Partners Inc | -0.680% | 2.083% | -19.672% | -29.327% | -25.758% | -41.527% | -35.526% |
News
EQS-News: M1 Kliniken AG reports strong EBIT Growth of 11% and achieves Earnings per Share of EUR 0.86.
EQS-News: M1 Kliniken AG reports strong EBIT Growth of 11% and achieves Earnings per Share of EUR 0.86.
EQS-Adhoc: M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group
EQS-Adhoc: M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group
EQS-News: M1 Kliniken AG: Successful First Half of 2025 with EBIT Growth of 24% and Earnings per Share of EUR 0.63
EQS-News: M1 Kliniken AG: Successful First Half of 2025 with EBIT Growth of 24% and Earnings per Share of EUR 0.63